NEW YORK, March 6, 2018 /PRNewswire/ -- CoolSculpting® teamed up with figure skating superstar and sports correspondent Johnny Weir to share his tips for looking his best at the CoolSculpting® on Ice event at The Rink at Rockefeller Center in New York City on Monday, March 5, 2018. Weir hosted an ice skating master class to discuss his life-long commitment to a healthy lifestyle, including his experience with the CoolSculpting® treatment CoolSculpting® is an FDA-cleared non-surgical, clinically proven treatment that eliminates stubborn fat using a patented cooling technology, owned by Allergan plc (NYSE: AGN).
Fans around the world are inspired by Weir's elegant yet edgy style, as well as the unpredictability of what he will say, wear or do. That is why CoolSculpting® enlisted the help of Weir to spread awareness around the "Not Cool vs. COOL" campaign, a multi-channel direct-to-consumer campaign which takes a lighthearted approach to extreme fat-loss methods and juxtaposes the 'cool' proven CoolSculpting® treatment with fat-loss methods that do not work. Weir takes the spotlight yet again in the hilarious "Not Cool vs. COOL" video series, which you can follow along using #COOLnotcool.
As an extension of the "Not Cool vs. COOL" campaign, Weir joined Dr. David Rapaport, a board-certified plastic surgeon in New York City, and Allergan executives at CoolSculpting® on Ice to share what is cool – and effective – in the aesthetics industry. Dr. Rapaport shared his insights on body contouring trends and common fat loss myths, as well as educated attendees on the CoolSculpting® treatment, based on proven science called Cryolipolysis® which exposes fat cells to extreme cold and triggers a natural elimination of the treated fat cells from the body for good.
"As a figure skater, I spend much of my life on camera in unforgiving costumes. While that is most people's worst nightmare, this is where I thrive," said CoolSculpting® Brand Ambassador Weir. "But even with my dedication to fitness, I can relate to the reality of having stubborn pockets of fat that are resistant to diet and exercise. There are many misleading myths and fads out there, but CoolSculpting® is proven to get rid of stubborn fat and it worked for me."
"Body contouring is one of the top four procedures consumers are considering2, among women and men alike," said Dr. Rapaport. "In my own practice, I have seen an increase in men interested in CoolSculpting® to help them maintain their fit physiques."
CoolSculpting® is clinically proven to be a safe and effective way to reduce stubborn fat. Results may be seen as early as three weeks, with the most dramatic results observed 1-3 months after treatment. CoolSculpting® is the only cold-based, non-surgical body contouring treatment cleared by the Food and Drug Administration. Some rare side effects include temporary numbness, discomfort and swelling. Please talk to a healthcare provider for additional information.
More photos from the CoolSculpting® on Ice event are available here. For more information about CoolSculpting®, please visit www.coolsculpting.com/.
1 2016 ASDS Survey on Dermatologic Procedures. Data collected for the 2016 experience from 16% of the 3,853 practicing members (627 physician respondents), and generalized to represent all ASDS members. CoolSculpting is the treatment doctors use most for non-invasive fat removal.
2 American Society for Dermatologic Surgery Consumer Survey on Cosmetic Dermatologic Procedures, 2017
About the CoolSculpting® Treatment
CoolSculpting® is a non-surgical, clinically proven treatment that selectively reduces unwanted fat using a patented cooling technology. Cleared by the FDA, CoolSculpting® works by gently cooling targeted fat cells in the body to induce a natural, controlled elimination of fat cells without affecting surrounding tissue, and the treated fat cells are gone for good. Millions of CoolSculpting® treatments have been performed in more than 80 countries. CoolSculpting® is available through a network of CoolSculpting® Centers worldwide. Dermatologists, plastic surgeons and aesthetic specialists that offer CoolSculpting can be found at www.coolsculpting.com.
In the U.S., the CoolSculpting® procedure is FDA-cleared for the treatment of visible fat bulges in the submental area, thigh, abdomen and flank, along with bra fat, back fat, underneath the buttocks (also known as banana roll), and upper arm. It is also FDA-cleared to affect the appearance of lax tissue with submental area treatments.
During the procedure you may experience sensations of pulling, tugging, mild pinching, intense cold, tingling, stinging, aching, and cramping at the treatment site. These sensations subside as the area becomes numb. Following the procedure, typical side effects include temporary redness, swelling, blanching, bruising, firmness, tingling, stinging, tenderness, cramping, aching, itching, or skin sensitivity, and sensation of fullness in the back of the throat after submental area treatment. Rare side effects may also occur. The CoolSculpting® procedure is not for everyone. You should not have the CoolSculpting® procedure if you suffer from cryoglobulinemia, cold agglutinin disease, or paroxysmal cold hemoglobinuria. The CoolSculpting® procedure is not a treatment for obesity. Please see full Important Safety Information for additional information.
Be sure to follow CoolSculpting on Facebook, Twitter, Pinterest and YouTube.
About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.
Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry with 55+ mid-to-late stage pipeline programs currently in development.
Allergan's success is powered by our more than 18,000 global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.
With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.
For more information, visit Allergan's website at www.Allergan.com.
Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; the impact of uncertainty around timing of generic entry related to key products, including RESTASIS®, on our financial results; uncertainty associated with financial projections, projected cost reductions, projected synergies, restructurings, increased costs, and adverse tax consequences; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2016 and Allergan's Quarterly Report on Form 10-Q for the period ended September 30, 2017. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.
View original content with multimedia:http://www.prnewswire.com/news-releases/coolsculpting-takes-to-the-ice-with-iconic-figure-skater-johnny-weir-to-debunk-fat-loss-myths-300608842.html
SOURCE CoolSculpting by Allergan